You are here: Home » News-ANI » Health
Business Standard

Discovery helps fight against drug-resistant TB

Topics
Health Medical Pharma

ANI 

Each year, approximately 10 million people fall ill with tuberculosis and around 1.7 million die from the devastating disease worldwide. One of the main antibiotics for TB is rifampicin, however, many strains of the tuberculosis-causing bacteria - Mycobacterium tuberculosis - have developed resistance to it.

Approximately 600,000 people are diagnosed with rifampicin-resistant tuberculosis every year. Now, researchers from Newcastle University and Demuris Ltd have identified that a naturally occurring antibiotic, called kanglemycin A - related to the antibiotic rifampicin - is active against rifampicin-resistant Mycobacterium tuberculosis.

It is hoped that this compound and the enhanced understanding gained from these studies may lead to effective new drug treatments in the future.

Nikolay Zenkin, lead author of the study, said: "Treatment of TB involves a cocktail of antibiotics administered over many months, and resistance to several key antibiotics is becoming a major public problem around the world. Our findings are very exciting and the first step towards developing a new, effective drug treatment for patients with rifampicin resistant TB to prevent fatalities in the future."

Dr Michael Hall, added: "This is an exciting development for the future treatment of rifampicin resistant TB and shows what can be achieved when local businesses and universities work together."

He said: "Recent development of drug-resistant Mycobacterium tuberculosis has made treatment of this disease even more challenging. Identifying new compounds that are effective against the rifampicin-resistant RNA polymerase is incredibly important for public "

The findings of the study have been published in the journal, Molecular Cell.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Sat, October 06 2018. 03:01 IST
RECOMMENDED FOR YOU
RECOMMENDED FOR YOU